Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ELTX

Elicio Therapeutics Inc.

Apr 26 • 04:00PM ET

8.99

Dollar change -0.11
Percentage change -1.21	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.15	Insider Own	28.52%	Shs Outstand	9.60M	Perf Week	7.02%
Market Cap	92.06M	Forward P/E	-	EPS next Y	-4.19	Insider Trans	71.04%	Shs Float	7.32M	Perf Month	20.51%
Income	-31.70M	PEG	-	EPS next Q	-1.10	Inst Own	3.46%	Short Float	0.85%	Perf Quarter	94.59%
Sales	0.00M	P/S	-	EPS this Y	45.69%	Inst Trans	-2.81%	Short Ratio	1.06	Perf Half Y	38.31%
Book/sh	1.18	P/B	7.59	EPS next Y	-10.85%	ROA	-79.32%	Short Interest	0.06M	Perf Year	19.87%
Cash/sh	1.33	P/C	6.76	EPS next 5Y	-	ROE	-114.98%	52W Range	2.96 - 24.39	Perf YTD	7.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.87%	ROI	-182.41%	52W High	-63.14%	Beta	0.71
Dividend TTM	-	Quick Ratio	1.67	Sales past 5Y	162.73%	Gross Margin	-	52W Low	203.72%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	1.67	EPS Y/Y TTM	97.46%	Oper. Margin	0.00%	RSI (14)	57.73	Volatility	6.61% 10.76%
Employees	32	Debt/Eq	0.61	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.00	Target Price	11.00
Option/Short	No / Yes	LT Debt/Eq	0.53	EPS Q/Q	56.43%	Payout	-	Rel Volume	0.64	Prev Close	9.10
Sales Surprise	-	EPS Surprise	-45.63%	Sales Q/Q	-	Earnings	Mar 29 BMO	Avg Volume	58.40K	Price	8.99
SMA20	3.36%	SMA50	38.10%	SMA200	26.72%	Trades		Volume	37,127	Change	-1.21%

Apr-25-24 08:30AM	Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-05-24 04:30PM	Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting (GlobeNewswire) +17.69%
Apr-02-24 07:53AM	ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Mar-29-24 08:30AM	Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-18-24 08:00AM	Elicio Therapeutics Announces $6.0 Million Private Placement Financing (GlobeNewswire) +28.00%
08:30AM	Loading…
Mar-06-24 08:30AM	Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-05-24 08:30AM	Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-25-24 09:00AM	Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors (GlobeNewswire) +16.67%
Jan-17-24 08:30AM	Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium (GlobeNewswire)
Jan-16-24 08:30AM	Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Jan-11-24 08:30AM	Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study (GlobeNewswire)
Jan-09-24 08:26AM	Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today? (InvestorPlace) -30.31%
06:00AM	Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 (GlobeNewswire)
Dec-22-23 09:00AM	Elicio Therapeutics Announces $7.0 Million Private Placement Financing (GlobeNewswire) +11.21%
Dec-04-23 08:00AM	Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire) +11.04%
04:30PM	Loading…
Nov-09-23 04:30PM	Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -18.76%
Nov-03-23 04:30PM	Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting (GlobeNewswire)
Oct-11-23 08:00AM	Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting (GlobeNewswire)
Sep-27-23 05:30PM	Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer (GlobeNewswire)
Sep-07-23 08:00AM	Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines (GlobeNewswire)
Sep-06-23 08:00AM	Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-05-23 08:00AM	Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer (GlobeNewswire) +6.46%
Aug-28-23 08:00AM	Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics (GlobeNewswire)
Aug-22-23 04:30PM	Elicio Therapeutics Reports Inducement Grants (GlobeNewswire)
Aug-11-23 08:30AM	Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-09-23 08:00AM	Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model (GlobeNewswire)
Jun-06-23 08:00AM	Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update (GlobeNewswire) -8.92%
Jun-03-23 09:00AM	Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting (GlobeNewswire)
Jun-02-23 04:30PM	Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer (GlobeNewswire) +81.45%

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chudnovsky Yekaterina	Director	Dec 22 '23	Buy	5.81	1,213,000	7,047,530	1,915,639	Dec 26 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELTX

Elicio Therapeutics Inc.

Upgrade your FINVIZ experience